Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 780.81M | 682.46M | 630.82M | 712.93M | 480.85M |
Gross Profit | 432.85M | 398.60M | 348.86M | 422.46M | 245.27M |
EBITDA | -1.01B | -1.21B | -1.24B | -1.46B | -1.29B |
Net Income | -1.02B | -1.22B | -1.24B | -1.48B | -1.29B |
Balance Sheet | |||||
Total Assets | 2.47B | 1.75B | 2.22B | 2.34B | 3.49B |
Cash, Cash Equivalents and Short-Term Investments | 2.06B | 1.33B | 1.73B | 1.79B | 2.69B |
Total Debt | 281.50M | 291.00M | 184.00M | 183.00M | 180.00M |
Total Liabilities | 548.55M | 593.73M | 424.72M | 446.39M | 384.59M |
Stockholders Equity | 1.92B | 1.16B | 1.79B | 1.89B | 3.11B |
Cash Flow | |||||
Free Cash Flow | -1.00B | -1.07B | -1.19B | -1.13B | -1.36B |
Operating Cash Flow | -1.00B | -1.07B | -1.19B | -1.13B | -1.36B |
Investing Cash Flow | 0.00 | 173.00K | 0.00 | -35.38M | -3.52M |
Financing Cash Flow | 1.74B | 667.30M | 1.13B | 271.35M | 1.94B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
79 Outperform | ¥11.72T | 28.59 | 22.80% | 3.51% | 17.96% | 25.65% | |
72 Outperform | $1.16T | 25.22 | 5.34% | 3.87% | 6.42% | 10.82% | |
67 Neutral | $6.01T | 20.67 | 17.60% | 1.86% | 17.77% | 49.34% | |
64 Neutral | ¥342.56B | 10.47 | -2.86% | 2.57% | 11.81% | -7.17% | |
62 Neutral | ¥355.58B | 15.05 | 13.50% | ― | 26.79% | ― | |
48 Neutral | ¥9.60B | ― | ― | 14.41% | 27.42% | ||
42 Neutral | $21.88B | ― | -193.61% | ― | 179.79% | -204.13% |
Chiome Bioscience Inc. has issued corrections to its previously released non-consolidated financial results for the fiscal year ended December 31, 2024. The corrections pertain to minor adjustments in cash flows from operating and financing activities, as well as details in the cost of sales. These adjustments reflect slight changes in financial figures, which may have implications for stakeholders analyzing the company’s financial health and operational efficiency.
Chiome Bioscience Inc. has entered a collaborative research agreement with OmniAb, Inc. to explore synergies in bispecific antibody generation. This partnership aims to implement a high throughput screening system, leveraging OmniAb’s OmniClic platform, to enhance Chiome’s antibody development capabilities and strengthen its profitability. The financial impact for the fiscal year ending December 2025 is expected to be minimal.
Chiome Bioscience Inc. reported a modest increase in net sales for the fiscal year 2024, reaching 780 million yen, reflecting a 14.4% rise from the previous year. Despite this growth, the company continues to face financial challenges with significant losses in operating and net income, indicating ongoing struggles within its operations. The financial position improved with an increase in total assets and net assets, showcasing a strengthened equity ratio. The company is cautious about its future financial results, particularly in the drug discovery and development sector, and has only provided forecasts for the drug discovery support business.
Chiome Bioscience Inc. announced the publication of a research paper in collaboration with Ceinge-Biotecnologie Avanzate, highlighting the effectiveness of their Tribody™ technology in cancer immunotherapy. The study demonstrated that their tri-specific Tribody™ antibody could enhance T cell responses more effectively than existing combination therapies by targeting tumor-associated antigens and immune checkpoint molecules. This advancement suggests significant potential for the Tribody™ technology to improve cancer treatment efficacy, potentially impacting the broader biotech and pharmaceutical sectors by reducing the complexity of cancer therapies for patients.